Amarin Corp Plc (AMRN)

[Chas42va]

Here is a my simple take on the Evaporate study

The Evaporate study showed that plaque was significantly reduce within only nine months (study going for 18 months total)– and had the most reduction for those with the worst situations. This was proven by imaging the arteries. Total plaque was reduced 42% however that was not part of the original target metrics hence the misinformation/confusion.

Also the cost-benefit study was very favorable -it shows that this was Dominant meaning the cost for the new drugs were less than the benefits received (lower cost overall). This is not usually the case is normally there is an increase cost to have some medical improvement. This supports the Reduce It study and also supports the label expansion and hence the future BLOCKBUSTER sales starting this coming year.
——

I believe ADA has Vascepa as part of their SOC – standard care and there are over 30 million diabetics and 70 million prediabetic‘s in the US alone versus only 400,000 patients on Vascepa today.


We should see some movement Today back to the 24/25 range -as yesterday’s drop off is a gift to be taken advantage of. This is a great set up for PDUFA on or before 12/28.

Looking forward to the analysts updating their numbers soon – currently high is 51 ( before the 16-0 vote) average is 33 prior to th e 16-0 vote and Evaporate
Long AMRN